Page last updated: 2024-09-04

glucagon and cilostamide

glucagon has been researched along with cilostamide in 2 studies

Compound Research Comparison

Studies (glucagon)	Trials (glucagon)	Recent Studies (post-2010) (glucagon)	Studies (cilostamide)	Trials (cilostamide)	Recent Studies (post-2010) (cilostamide)
26,039	1,498	3,054	192	0	67

Protein Interaction Comparison

Protein	Taxonomy	cilostamide (IC50)
cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)	0.005
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A	Homo sapiens (human)	0.005
cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)	3.5775
Platelet-activating factor receptor	Homo sapiens (human)	3.687
cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)	0.005
cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)	0.0502
cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)	0.0362

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Benelli, C; Desbuquois, B; Fouque, F; Geoffroy, V; Lugnier, C	1
Hernández, J; Juan-Fita, MJ; Vargas, ML	1

Other Studies

2 other study(ies) available for glucagon and cilostamide

Article	Year
Characterization of an in vivo hormonally regulated phosphodiesterase 3 (PDE3) associated with a liver Golgi-endosomal fraction. Archives of biochemistry and biophysics, 2001, Mar-01, Volume: 387, Issue:1 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Endosomes; Gene Expression Regulation, Enzymologic; Glucagon; Golgi Apparatus; Growth Hormone; Hormones; Insulin; Isoenzymes; Liver; Male; Obesity; Phosphodiesterase Inhibitors; Pyridazines; Quinolones; Rats; Rats, Zucker; Subcellular Fractions	2001
The phosphodiesterase 3 inhibitor cilostamide enhances inotropic responses to glucagon but not to dobutamine in rat ventricular myocardium. European journal of pharmacology, 2005, Apr-11, Volume: 512, Issue:2-3 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenine; Adrenergic beta-Antagonists; Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Dobutamine; Dose-Response Relationship, Drug; Drug Synergism; Exonucleases; Female; Glucagon; Heart Ventricles; Imidazoles; In Vitro Techniques; Male; Myocardial Contraction; Phosphodiesterase I; Phosphodiesterase Inhibitors; Purinergic P1 Receptor Antagonists; Quinolones; Rats; Rats, Sprague-Dawley; Ventricular Function; Xanthines	2005

Article

Year

Characterization of an in vivo hormonally regulated phosphodiesterase 3 (PDE3) associated with a liver Golgi-endosomal fraction.

Archives of biochemistry and biophysics, 2001, Mar-01, Volume: 387, Issue:1

Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Endosomes; Gene Expression Regulation, Enzymologic; Glucagon; Golgi Apparatus; Growth Hormone; Hormones; Insulin; Isoenzymes; Liver; Male; Obesity; Phosphodiesterase Inhibitors; Pyridazines; Quinolones; Rats; Rats, Zucker; Subcellular Fractions

2001

The phosphodiesterase 3 inhibitor cilostamide enhances inotropic responses to glucagon but not to dobutamine in rat ventricular myocardium.

European journal of pharmacology, 2005, Apr-11, Volume: 512, Issue:2-3

Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenine; Adrenergic beta-Antagonists; Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Dobutamine; Dose-Response Relationship, Drug; Drug Synergism; Exonucleases; Female; Glucagon; Heart Ventricles; Imidazoles; In Vitro Techniques; Male; Myocardial Contraction; Phosphodiesterase I; Phosphodiesterase Inhibitors; Purinergic P1 Receptor Antagonists; Quinolones; Rats; Rats, Sprague-Dawley; Ventricular Function; Xanthines

2005